142 related articles for article (PubMed ID: 38779875)
1. The prognostic value of metabolic dysfunction-associated steatotic liver disease in acute myocardial infarction: A propensity score-matched analysis.
Kong G; Cao G; Koh J; Chan SP; Zhang A; Wong E; Chong B; Jauhari SM; Wang JW; Mehta A; Figtree GA; Mamas MA; Ng G; Chan KH; Chai P; Low AF; Lee CH; Yeo TC; Yip J; Foo R; Tan HC; Huang DQ; Muthiah M; Chan MY; Loh PH; Chew NWS
Diabetes Obes Metab; 2024 May; ():. PubMed ID: 38779875
[TBL] [Abstract][Full Text] [Related]
2. Severity and Remission of Metabolic Dysfunction-Associated Fatty/Steatotic Liver Disease With Chronic Kidney Disease Occurrence.
Gao J; Li Y; Zhang Y; Zhan X; Tian X; Li J; Wang R; He Y; Wang A; Wu S
J Am Heart Assoc; 2024 Mar; 13(5):e032604. PubMed ID: 38390843
[TBL] [Abstract][Full Text] [Related]
3. Association of Metabolic Dysfunction-Associated Steatotic Liver Disease/Non-alcoholic Fatty Liver Disease With Type 2 Diabetes Mellitus: A Case-Control Study in a Tertiary Care Hospital in Pakistan.
Zahoor F; Saeed NU; Javed S; Sadiq HZ; Mand Khan F; Haider M; Shafqat MN; Maqbool A; Chaudhry A
Cureus; 2023 Oct; 15(10):e47240. PubMed ID: 38021965
[TBL] [Abstract][Full Text] [Related]
4. Hepatic steatosis and advanced hepatic fibrosis are independent predictors of long-term mortality in acute myocardial infarction.
Chin Y; Lim J; Kong G; Ng CH; Goh R; Muthiah M; Mehta A; Chong B; Lin C; Chan KE; Kong W; Poh KK; Foo R; Chai P; Yeo TC; Low AF; Lee CH; Tan HC; Chan MY; Richards AM; Loh PH; Chew NWS
Diabetes Obes Metab; 2023 Apr; 25(4):1032-1044. PubMed ID: 36546614
[TBL] [Abstract][Full Text] [Related]
5. Insulin resistance and central obesity determine hepatic steatosis and explain cardiovascular risk in steatotic liver disease.
Semmler G; Balcar L; Wernly S; Völkerer A; Semmler L; Hauptmann L; Wernly B; Aigner E; Niederseer D; Datz C
Front Endocrinol (Lausanne); 2023; 14():1244405. PubMed ID: 37842290
[TBL] [Abstract][Full Text] [Related]
6. Validation of the new nomenclature of steatotic liver disease in patients with a history of excessive alcohol intake: an analysis of data from a prospective cohort study.
Israelsen M; Torp N; Johansen S; Hansen CD; Hansen ED; Thorhauge K; Hansen JK; Villesen I; Bech K; Wernberg C; Andersen P; Lindvig KP; Tsochatzis EA; Thiele M; Rinella ME; Krag A;
Lancet Gastroenterol Hepatol; 2024 Mar; 9(3):218-228. PubMed ID: 38218202
[TBL] [Abstract][Full Text] [Related]
7. Clinical profiles and mortality rates are similar for metabolic dysfunction-associated steatotic liver disease and non-alcoholic fatty liver disease.
Younossi ZM; Paik JM; Stepanova M; Ong J; Alqahtani S; Henry L
J Hepatol; 2024 May; 80(5):694-701. PubMed ID: 38286339
[TBL] [Abstract][Full Text] [Related]
8. Prognostic value of metabolic dysfunction-associated steatotic liver disease over coronary computed tomography angiography findings: comparison with no-alcoholic fatty liver disease.
Nishihara T; Miyoshi T; Nakashima M; Miki T; Toda H; Yoshida M; Ichikawa K; Osawa K; Yuasa S
Cardiovasc Diabetol; 2024 May; 23(1):167. PubMed ID: 38730426
[TBL] [Abstract][Full Text] [Related]
9. MASLD, hepatic steatosis and fibrosis are associated with the prevalence of chronic kidney disease and retinopathy in adults with type 1 diabetes mellitus.
Mantovani A; Morieri ML; Aldigeri R; Palmisano L; Masulli M; Bonomo K; Baroni MG; Cossu E; Cimini FA; Cavallo G; Buzzetti R; Mignogna C; Leonetti F; Bacci S; Trevisan R; Pollis RM; Cas AD; de Kreutzenberg SV; Targher G
Diabetes Metab; 2024 Jan; 50(1):101497. PubMed ID: 37992857
[TBL] [Abstract][Full Text] [Related]
10. Estimated pulse wave velocity in metabolic dysfunction-associated steatotic liver disease and all-cause/cause-specific mortality.
Kim D; Manikat R; Wijarnpreecha K; Cholankeril G; Ahmed A
J Gastroenterol Hepatol; 2024 May; ():. PubMed ID: 38740513
[TBL] [Abstract][Full Text] [Related]
11. Impact of metabolic dysfunction-associated steatotic liver disease on COVID-19 hospitalizations: A propensity-matched analysis of the United States.
Sohail A; Ali H; Patel P; Subramanium S; Dahiya DS; Sohail AH; Gangwani MK; Satapathy SK
World J Virol; 2024 Mar; 13(1):91149. PubMed ID: 38616849
[TBL] [Abstract][Full Text] [Related]
12. Longitudinal Outcomes Associated With Metabolic Dysfunction-Associated Steatotic Liver Disease: A Meta-analysis of 129 Studies.
Chan KE; Ong EYH; Chung CH; Ong CEY; Koh B; Tan DJH; Lim WH; Yong JN; Xiao J; Wong ZY; Syn N; Kaewdech A; Teng M; Wang JW; Chew N; Young DY; Know A; Siddiqui MS; Huang DQ; Tamaki N; Wong VW; Mantzoros CS; Sanyal A; Noureddin M; Ng CH; Muthiah M
Clin Gastroenterol Hepatol; 2024 Mar; 22(3):488-498.e14. PubMed ID: 37775028
[TBL] [Abstract][Full Text] [Related]
13. Fatty Liver Index (FLI) is the best score to predict MASLD with 50% lower cut-off value in women than in men.
Crudele L; De Matteis C; Novielli F; Di Buduo E; Petruzzelli S; De Giorgi A; Antonica G; Berardi E; Moschetta A
Biol Sex Differ; 2024 May; 15(1):43. PubMed ID: 38760802
[TBL] [Abstract][Full Text] [Related]
14. Impact of HIV Infection on Liver and Cardiovascular Outcomes in Veterans With Metabolic Dysfunction-Associated Steatotic Liver Disease.
Wong RJ; Yang Z; Yeoh A; Do A; Ahmed A; Cheung R
Am J Gastroenterol; 2024 Apr; ():. PubMed ID: 38477465
[TBL] [Abstract][Full Text] [Related]
15. Metabolic dysfunction-associated steatotic liver disease increases the risk of incident cardiovascular disease: a nationwide cohort study.
Moon JH; Jeong S; Jang H; Koo BK; Kim W
EClinicalMedicine; 2023 Nov; 65():102292. PubMed ID: 37954905
[TBL] [Abstract][Full Text] [Related]
16. Metabolomic Phenotype of Hepatic Steatosis and Fibrosis in Mexican Children Living with Obesity.
Garibay-Nieto N; Pedraza-Escudero K; Omaña-Guzmán I; Garcés-Hernández MJ; Villanueva-Ortega E; Flores-Torres M; Pérez-Hernández JL; León-Hernández M; Laresgoiti-Servitje E; Palacios-González B; López-Alvarenga JC; Lisker-Melman M; Vadillo-Ortega F
Medicina (Kaunas); 2023 Oct; 59(10):. PubMed ID: 37893503
[No Abstract] [Full Text] [Related]
17. MASLD/MetALD and mortality in individuals with any cardio-metabolic risk factor: A population-based study with 26.7 years of follow-up.
Kwak M; Kim HS; Jiang ZG; Yeo YH; Trivedi HD; Noureddin M; Yang JD
Hepatology; 2024 May; ():. PubMed ID: 38739848
[TBL] [Abstract][Full Text] [Related]
18. Metabolic dysfunction-associated steatotic liver disease increases hepatocellular carcinoma risk in chronic hepatitis B patients: a retrospective cohort study.
Lin M; Gao B; Peng M; Chen X; Xiao H; Shi M; Zhang X; Zeng F; Chi X
Front Physiol; 2024; 15():1347459. PubMed ID: 38405121
[No Abstract] [Full Text] [Related]
19. Incident cardiac arrhythmias associated with metabolic dysfunction-associated steatotic liver disease: a nationwide histology cohort study.
Simon TG; Ebrahimi F; Roelstraete B; Hagström H; Sundström J; Ludvigsson JF
Cardiovasc Diabetol; 2023 Dec; 22(1):343. PubMed ID: 38093277
[TBL] [Abstract][Full Text] [Related]
20. Familial coaggregation of MASLD with hepatocellular carcinoma and adverse liver outcomes: Nationwide multigenerational cohort study.
Ebrahimi F; Hagström H; Sun J; Bergman D; Shang Y; Yang W; Roelstraete B; Ludvigsson JF
J Hepatol; 2023 Dec; 79(6):1374-1384. PubMed ID: 37647992
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
